vTv Therapeutics Inc. (VTVT)
Stock Price:
$2.06 USD
0.00 (0.00%)
Updated December 2, 4:00 PM EST - Market closed
Pre-market: $2.00 -0.06 (-2.91%) Dec 3, 8:58 AM
Key Info
| Market Cap |
104.62M |
| Revenue (ttm) |
22,000 |
| Net Income (ttm) |
-14.66M |
| Shares Out |
71.05M |
| EPS (ttm) |
-0.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 2 |
| Last Price |
$2.06 |
| Previous Close |
$2.06 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
2.03 |
| Day's Range |
1.90 - 2.11 |
| Day's Volume |
957,524 |
| 52-Week Range |
1.49 - 3.75 |
More Stats
| Market Cap |
104.62M |
| Enterprise Value |
106.03M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
71.05M |
| Float |
n/a |
| EPS (basic) |
-0.34 |
| EPS (diluted) |
-0.33 |
| FCF / Share |
-0.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.09M |
| Short Ratio |
2.32 |
| Short % of Float |
n/a |
| Beta |
-2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4,755.43 |
| PB Ratio |
n/a |
| Revenue |
22,000 |
| Operating Income |
-19.24M |
| Net Income |
-14.66M |
| Free Cash Flow |
-21.73M |
| Net Cash |
-1.41M |
| Net Cash / Share |
-0.03 |
| Gross Margin |
-56,159.09% |
| Operating Margin |
-87,468.18% |
| Profit Margin |
-66,627.30% |
| FCF Margin |
-98,781.82% |
| ROA |
-155.17% |
| ROE |
n/a |
| ROIC |
2,094.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.00*
(239.81% upside)
Low
6.00
Current: $2.06
High
8.00
Target: 7.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 2.76 | 12.43 | 0.29 | 0.63 | 0.52 | 1.55 | 0.98 |
| Revenue Growth | -77.77% | 4172.85% | -54.1% | 22.16% | -66.49% | 58.71% | - |
| Gross Profit | 2.76 | 12.43 | 0.29 | 0.63 | 0.52 | 1.55 | 0.98 |
| Operating Income | -20.07 | -20.46 | -50.87 | -55.02 | -38.14 | -28.90 | -35.83 |
| Net Income | -13.04 | -7.91 | -16.14 | -16.35 | -27.50 | -36.10 | -48.20 |
| Shares Outstanding | 59.90 | 40.75 | 32.81 | 32.81 | 32.81 | - | - |
| Earnings Per Share | -0.59 | -0.69 | -1.67 | -1.71 | -3.32 | - | - |
| Operating Cash Flow | -23.02 | -26.86 | -44.56 | -48.21 | -36.95 | -30.78 | -41.68 |
| Capital Expenditures | 0.24 | 0.01 | -0.03 | -0.08 | -0.08 | 0.30 | -0.16 |
| Free Cash Flow | -22.78 | -26.85 | -44.59 | -48.29 | -37.03 | -30.48 | -41.84 |
| Cash & Equivalents | 1.78 | 1.68 | 11.92 | 51.51 | 88.00 | 1.51 | - |
| Total Debt | 7.11 | 15.71 | 19.59 | 11.06 | - | 36.17 | - |
| Net Cash / Debt | -5.34 | -14.03 | -7.67 | 40.45 | 88.00 | -34.66 | - |
| Assets | 9.27 | 8.56 | 27.92 | 54.50 | 91.53 | 12.95 | - |
| Liabilities | 18.11 | 28.93 | 47.52 | 22.93 | 7.97 | 73.67 | - |
| Book Value | -49.02 | -82.85 | -151 | -90.95 | -77.97 | -499 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
vTv Therapeutics Inc. |
| Country |
United States |
| Employees |
26 |
| CEO |
Stephen Holcombe |
Stock Information
| Ticker Symbol |
VTVT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VTVT |
| IPO Date |
July 30, 2015 |
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Company; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.